N-(pivaloyl)glycinohydroxamic acid

effectively inhibits alkalinization of urine & stone formation in vivo & in vitro due to strong inhibitory potentcy against ureolytic activity of intact Proteus mirabilis; high renal clearance & no mutagenicity

Also Known As:

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Urolithiasis 07/01/1981 - "With the aim of finding a prospective therapeutic compound with a promising potential for the treatment of urolithiasis, we evaluated the effectiveness of a new potent inhibitor of urease, N-(pivaloyl)glycinohydroxamic acid. " 04/01/1991 - "Evaluation of effects of novel urease inhibitor, N-(pivaloyl)glycinohydroxamic acid on the formation of an infection bladder stone using a newly designed urolithiasis model in rats."
2.	Urinary Calculi (Urinary Calculus) 07/01/1981 - "IV. Prevention of infected urinary stone formation with N-(pivaloyl)glycinohydroxamic acid." 01/01/1982 - "The effectiveness of a new urease inhibitor, N-(pivaloyl)glycinohydroxamic acid, in the treatment of infected urinary stones was investigated. " 01/01/1982 - "Treatment of infected urinary stones in rats by a new hydroxamic acid, "N-(pivaloyl)glycinohydroxamic acid."
3.	Urinary Tract Infections (Urinary Tract Infection) 04/01/1991 - "The oral dosing of P-GHA significantly inhibited the elevation of the urinary ammonia level of rats having the urinary tract infection with Proteus mirabilis. "
4.	Infections 04/01/1991 - "A short term regimen (7 d, 730 +/- 38 mg/kg) with P-GHA significantly inhibited the development of the infection bladder stone. " 04/01/1991 - "Furthermore, a long term combination regimen (11 d) of P-GHA and aminobenzylpenicillin markedly inhibited the development of the infection bladder stone, and also caused a very slight renal impairment to the rats tested in contrast with the method of Vermeulen et al. Our infection stone model in rats, therefore, seems to be useful for the evaluation of therapeutic agents in long term examinations." 04/01/1991 - "Evaluation of effects of novel urease inhibitor, N-(pivaloyl)glycinohydroxamic acid on the formation of an infection bladder stone using a newly designed urolithiasis model in rats." 04/01/1991 - "By using our new infection stone model of a rat, we evaluated the effect of a novel urease inhibitor, N-(pivaloyl)glycinohydroxamic acid (P-GHA), on the formation of an infection bladder stone. "
5.	Urinary Bladder Calculi (Bladder Calculi) 04/01/1991 - "A short term regimen (7 d, 730 +/- 38 mg/kg) with P-GHA significantly inhibited the development of the infection bladder stone. " 04/01/1991 - "Furthermore, a long term combination regimen (11 d) of P-GHA and aminobenzylpenicillin markedly inhibited the development of the infection bladder stone, and also caused a very slight renal impairment to the rats tested in contrast with the method of Vermeulen et al. Our infection stone model in rats, therefore, seems to be useful for the evaluation of therapeutic agents in long term examinations." 04/01/1991 - "Evaluation of effects of novel urease inhibitor, N-(pivaloyl)glycinohydroxamic acid on the formation of an infection bladder stone using a newly designed urolithiasis model in rats." 04/01/1991 - "By using our new infection stone model of a rat, we evaluated the effect of a novel urease inhibitor, N-(pivaloyl)glycinohydroxamic acid (P-GHA), on the formation of an infection bladder stone. "

Related Drugs and Biologics

1.	Urease
2.	N-(pivaloyl)glycinohydroxamic acid
3.	Hydroxamic Acids (Hydroxamic Acid)
4.	Ampicillin (Omnipen)
5.	Ammonia